NP0138-19E

General

Cell Line

hPSCreg name UKKi031-B
Cite as:
UKKi031-B (RRID:CVCL_RM75)
Alternative name(s)
NP0138-19E
Cell line type Human induced pluripotent stem cell (hiPSC)
Similar lines
UKKi031-A
(NP0138-8B)
Donor's gene variants:
TNNT2
Donor diseases:
Rare hypertrophic cardiomyopathy
UKKi031-C
(NP0138-31B)
Donor's gene variants:
TNNT2
Donor diseases:
Rare hypertrophic cardiomyopathy
UKKi025-A
(NP0135-1)
Donor's gene variants:
MYH7
Donor diseases:
Rare hypertrophic cardiomyopathy
UKKi017-B
(NP0075-10K)
Donor diseases:
Rare hypertrophic cardiomyopathy
UKKi017-C
(NP0075-11B)
Donor diseases:
Rare hypertrophic cardiomyopathy
UKKi025-B
(NP0135-2)
Donor's gene variants:
MYH7
Donor diseases:
Rare hypertrophic cardiomyopathy
UKKi025-C
(NP0135-7)
Donor's gene variants:
MYH7
Donor diseases:
Rare hypertrophic cardiomyopathy
UKKi035-B
(NP0139-B, NP0139-6C)
Donor's gene variants:
MYBPC3, MYBPC3
Donor diseases:
Rare hypertrophic cardiomyopathy
UKKi035-A
(NP0139-A, NP0139-3E)
Donor's gene variants:
MYBPC3, MYBPC3
Donor diseases:
Rare hypertrophic cardiomyopathy
UKKi035-C
(NP0139-C, NP0139-24D)
Donor's gene variants:
MYBPC3, MYBPC3
Donor diseases:
Rare hypertrophic cardiomyopathy
SCVIi037-A
(SCVI672)
Donor diseases:
hypertrophic cardiomyopathy
CIRMi929-A
(CW30245)
Donor diseases:
Hypertrophic Cardiomyopathy
WTSIi461-B
(HPSI0316i-eoko_3)
Donor diseases:
Rare hypertrophic cardiomyopathy
CIRMi893-A
(CW30205)
Donor diseases:
Hypertrophic Cardiomyopathy
SCVIi036-A
(SCVI248)
Donor diseases:
hypertrophic cardiomyopathy
CIRMi909-A
(CW30224)
Donor diseases:
Hypertrophic Cardiomyopathy
CIRMi919-A
(CW30234)
Donor diseases:
Hypertrophic Cardiomyopathy
ZJUi011-A
(ZJULLi003-A, LSYMYH7iPS)
Donor diseases:
Hypertrophic cardiomyopathy
CIRMi920-A
(CW30235)
Donor diseases:
Hypertrophic Cardiomyopathy
ZJUi012-A
(ZJULLi004-A, ZYLMYBPC3iPS)
Donor diseases:
Hypertrophic cardiomyopathy
WTSIi609-A
(HPSI0516i-suqd_3)
Donor diseases:
Rare hypertrophic cardiomyopathy
CIRMi937-A
(CW30256)
Donor diseases:
Hypertrophic Cardiomyopathy
CIRMi947-A
(CW30266)
Donor diseases:
Hypertrophic Cardiomyopathy
WTSIi679-B
(HPSI0316i-ponl_4)
Donor diseases:
Rare hypertrophic cardiomyopathy
TAUi001-A
(UTA.09703.HCMJp)
Donor's gene variants:
JPH2
Donor diseases:
hypertrophic cardiomyopathy
TAUi001-A-1
(JPH2)
Donor's gene variants:
JPH2
Donor diseases:
hypertrophic cardiomyopathy
PUMCHi002-A
(20180908R-AE3, PUMCH-IRC)
Donor diseases:
Restrictive Cardiomyopathy
ITXi004-A
(MS381)
Donor diseases:
Long QT Syndrome
FAMRCi006-A
(LMNA T3)
Donor's gene variants:
LMNA
Donor diseases:
Emery-Dreifuss Muscular Dystrophy
Dilated Cardiomyopathy
FAMRCi006-B
(LMNA T4)
Donor's gene variants:
LMNA
Donor diseases:
Emery-Dreifuss Muscular Dystrophy
Dilated Cardiomyopathy
USFi003-A
(1AB1)
Donor diseases:
Dilated Cardiomyopathy
YUCMi022-A
(hiPSC-KCNH2_G53S)
Donor diseases:
Long QT Syndrome
FAMRCi010-A
(RCMP48)
Donor's gene variants:
FLNC
Donor diseases:
Restrictive Cardiomyopathy
ITXi003-A
(MS368)
Donor diseases:
Long QT Syndrome
FAMRCi009-A
(RCMP43)
Donor's gene variants:
FLNC
Donor diseases:
Restrictive Cardiomyopathy
ISMMSi046-A
(PLN-R14del-3BC7)
Donor diseases:
Cardiomyopathy
FAMRCi005-A
(LMNA B4)
Donor's gene variants:
LMNA
Donor diseases:
myopathy
atrioventricular block
Paroxysmal ventricular tachycardia
FAMRCi005-B
(LMNA B5)
Donor's gene variants:
LMNA
Donor diseases:
myopathy
atrioventricular block
Paroxysmal ventricular tachycardia
Last update 6th December 2019
User feedback
No feedback available yet.

Login to share your feedback, experiences or results with the research community.

Provider

Generator Klinikum der Universität zu Köln (UKK)
Distributors
Derivation country Germany

External Databases

BioSamples SAMEA104494415
EBiSC UKKi031-B
Cellosaurus CVCL_RM75
Wikidata Q54990528

General Information

Projects
* Is the cell line readily obtainable for third parties?
Yes
Research use: allowed
Clinical use: allowed
Commercial use: allowed

Donor Information

General Donor Information

Sex female
Age of donor (at collection) 55-59

Phenotype and Disease related information (Donor)

Diseases A disease was diagnosed.
Tnnt2; Exon 9; c.281G>T; Arg94Leu
The donor is a carrier of a disease-associated mutation and affected.
Genetic variants
TNNT2 (target)
1q32.1
NM_001001430.2:c.281G>T
NP_001001430.1:p.Arg94Leu
Heterozygous
Please explain briefly the supporting evidence
Family history No
Is the medical history available upon request? yes
Is clinical information available? yes

Karyotyping (Donor)

Has the donor karyotype been analysed?
No

Other Genotyping (Donor)

Is there genome-wide genotyping or functional data available?
No

Donor Relations

Other cell lines of this donor

External Databases (Donor)

BioSamples SAMEA104494414

Ethics

Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? Yes
Was the consent voluntarily given? Yes
Has the donor been informed that participation will not directly influence their personal treatment? Yes
Can you provide us with a copy of the Donor Information Sheet provided to the donor? Yes
Do you (Depositor/Provider) hold the original Donor Consent Form? No
If you do not hold the Donor Consent Form, do you know who does? Yes
Please provide the contact information Tomo Saric
Alternatives to consent are available? No
Is there other documentation provided to the donor for consenting purposes? No
Confirm that consent was obtained by a qualified professional Yes
Has the donor agreed to be re-contacted? Yes
Has the donor been informed about how her/his data will be protected? Yes
Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. pseudonymised
Does consent explicitly allow the derivation of pluripotent stem cells? Yes
Does consent expressly prevent the derivation of pluripotent stem cells? No
Does consent pertain to a specific research project? No
Does consent permit unforeseen future research, without further consent? Yes
Does the consent permit uses of donated embryo/tissue or derived cell line intended for clinical treatment or human applications? No
Does consent expressly prevent development of commercial products? No
Does consent expressly prevent financial gain from any use of the donated embryo/tissue, including any product made from it? No
Does consent expressly permit storage of donated embryo/tissue for an unlimited time? Yes
Does consent expressly permit storage of cells derived from the donated embryo/tissue for an unlimited time? Yes
Does consent prevent the DONATED BIOSAMPLE from being made available to researchers anywhere in the world? No
Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? No

Does consent permit research by

an academic institution? Yes
a public organisation? Yes
a non-profit company? Yes
a for-profit corporation? Yes
Does consent expressly permit collection of genetic information? Yes
Does consent expressly permit storage of genetic information? Yes
Does consent prevent dissemination of genetic information? No
Has the donor been informed that their donated biosample or derived cells may be tested for the presence of microbiological agents / pathogens? Yes
Has the donor consented to receive information discovered during use of donated embryo/tissue that has significant health implications for the donor? No
How may genetic information associated with the cell line be accessed? Controlled Access
Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? No
Does the consent anticipate that the donor will be notified of results or outcomes of any research involving the donated samples or derived cells? No
Does the consent permit the donor, upon withdrawal of consent, to stop the use of the derived cell line(s) that have already been created from donated samples? No
Does the consent permit the donor, upon withdrawal of consent, to stop delivery or use of information and data about the donor? No
Does consent permit access to medical records of the donor? Yes
Please describe how access is provided: Clinic in which the donor was recruted holds the medical records
Does consent permit access to any other source of information about the clinical treatment or health of the donor? Yes
Contact data, institution, or website:
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? Yes
Name of accrediting authority involved? Independent Ethics Committee of the Faculty of Medicin of the University of Cologne
Approval number DRKS00009433
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? Yes
Name of accrediting authority involved? Committee of the Faculty of Medicin of the University of Cologne
Approval number DRKS00009433
Do you have obligations to third parties in regard to the use of the cell line? No
Are you aware of any further constraints on the use of the donated embryo/tissue or derived cells? No
Is there an MTA available for the cell line? Yes
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? Thermo Fisher (CytoTune iPS 2.0 Sendai Reprogramming Kit)
Are you aware of any constraints on the use or distribution of the cell line from the owner or any parties identified in the query above? No

hIPSC Derivation

General

Source cell type
A leukocyte with a single non-segmented nucleus in the mature form found in the circulatory pool of blood.
Source cell type (free text) UKK Cologne
Age of donor (at collection) 55-59
Collected in 2016
Passage number reprogrammed 0

Reprogramming method

Vector type Non-integrating
Vector Sendai virus
Genes
Is reprogramming vector detectable?
No
Methods used
PCR
Files and images showing reprogramming vector expressed or silenced

Vector free reprogramming

Type of used vector free reprogramming factor(s)
None

Other

Selection criteria for clones morphology
Derived under xeno-free conditions
Yes
Derived under GMP?
No
Available as clinical grade?
No

Culture Conditions

Surface coating Vitronectin
Feeder cells
No
Passage method Enzyme-free cell dissociation
EDTA
O2 Concentration 20 %
CO2 Concentration 5 %
Medium Other medium:
Base medium: StemFlex
Main protein source: Albumine
Serum concentration: 0 %
Supplements
StemFlex Supplement 10x 50 ml
Has Rock inhibitor (Y27632) been used at passage previously with this cell line?
No
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line?
No
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line?
No

Characterisation

Analysis of Undifferentiated Cells
Marker Expressed Immunostaining RT-PCR Flow Cytometry Enzymatic Assay Expression Profiles
TRA 1-80
Yes
OCT 4
Yes
NANOG
Yes
SSEA-4
Yes
SOX2
Yes
FOXD3
Yes
DNMT3b
Yes
Morphology pictures
Differentiation Potency
Endoderm
Ont Id: UBERON_0000925
In vitro directed differentiation
Marker Expressed
SOX17
Yes
Morphology
Mesoderm
Ont Id: UBERON_0000926
In vitro directed differentiation
Marker Expressed
BRACHYURY
Yes
Morphology
Ectoderm
Ont Id: UBERON_0000924
In vitro directed differentiation
Morphology

Microbiology / Virus Screening

HIV 1 Negative
HIV 2 Negative
Hepatitis B Negative
Hepatitis C Negative
Mycoplasma Negative

Genotyping

Karyotyping (Cell Line)

Has the cell line karyotype been analysed?
Yes
No larger chromosomal aberrations to be reported; Chr20: Duplication in q11.21.
Passage number: 18
Karyotyping method: Molecular karyotyping by SNP array

Other Genotyping (Cell Line)

Is there genome-wide genotyping or functional data available?
Yes